{
    "symbol": "ARGX",
    "quarter": 2,
    "year": 2022,
    "date": "2022-07-28 13:00:27",
    "content": " To begin, the second quarter of our VYVGART launch showed significant growth from the first quarter with global net product sales of USD75 million This will expand on our programs across our patients, physician and payer segments late in the call. This is why we come to work every day to be able to improve the lives of patients and the label solutions to those who need them, bring more optionality to the gMG community with our project subcu product launch, advance our best-in-class FcRn pipeline, with Phase 3 data readouts of efgartigimod in three indications next year, expand our next pipeline in the product opportunity with our first-in-class C2 inhibitors ARGX-117 and further develop our earlier assets that have emerged from our unique discovery engine including ARGX-119. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Hi, good morning and thanks for taking the questions. Your line is open. Your line is open. Your line is open. So as far as opening up additional audiences, really the unmet medical need and the success that patients and physicians are seeing with VYVGART is why we've had pretty substantial demand here in the first couple of quarters. Your line is open. Your line is open. Your line is open. Your line is open. Hi, thanks for taking the question. Your line is open. Your line is open. Your line is open. Your line is open. Hi, good morning and thanks for taking the questions. The good news is I think that those physicians see that experience and the experience that their patient is having, that's where we have the opportunity, the real opportunity to advance earlier into the treatment paradigm, but also take that 78% and take them from being with one or two patients on therapy to now even more than that. Your line is open. Hi, thanks for taking the question. Your line is open."
}